This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

InterMune's CEO Discusses France's Economic Committee's (CEPS) Authorization Of Reimbursement Of Esbriet Conference (Transcript)

We are very pleased with this price. In particular for comparison with what we view as relevant analogs in France, the Esbriet price is similar to the current price of Tracleer, an oral drug for pulmonary arterial hypertension and that is priced at €25750 and the prices for the treatments of lung cancer such as Tarceva or Iressa are in the same -- very much in the same range at the price granted for Esbriet in France.

In addition the Esbriet price is above those of the multiple sclerosis drugs Tysabri and Gilenya which are priced in France at €23500 and €22700 respectively. So within this context we are very, very pleased with the Esbriet price. Esbriet will be reimbursable after it is published in the French Journal Officiel year which we expect to happen in the fourth quarter of this year. We are planning to launch Esbriet as soon as possible after this publication of the Esbriet price in French Journal Officiel. And when our commercial team is fully recruited and trained to promote Esbriet.

We therefore currently expect the launch to be in December of this year. Esbriet will be reimbursed by the French National Health Insurance System for the treatment of mild to moderate forms of IPF in adults. Esbriet will be reimbursed as a [medicamom dexepsion] which means that it will be reimbursed for the labeled indication defined previously by the Transparency Commission or CT as IPF patients with forced vital capacity greater than or equal to 50% and DLCO greater than or equal to 35%.

You may recall that these metrics correspond to the lung function entry criteria, the bottom end of those criteria for our capacity Phase III program. In terms of post marketing commitments we have committed to conduct a patient registry to capture information regarding the use of Esbriet in everyday clinical practice.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs